Effects on caregiver burden of a donepezil hydrochloride dosage increase to 10 mg/day in patients with Alzheimer’s disease
Authors Nakamura K, Watanabe N, Ohkawa H, Ando M, Ogura Y, Funabiki S, Kume A, Urano K, Osada T, Yamamura K
Received 21 June 2014
Accepted for publication 7 August 2014
Published 15 September 2014 Volume 2014:8 Pages 1223—1228
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Dr Johnny Chen
Kazuhito Nakamura,1,2 Norio Watanabe,1 Hiroshi Ohkawa,3 Michiyasu Ando,4 Yukio Ogura,5 Sumito Funabiki,6 Akito Kume,7 Kimihiko Urano,1 Takashi Osada,1 Keiko Yamamura1
1Department of Clinical Pharmacy, School of Pharmacy, Aichi Gakuin University, 2Koyo Pharmacy, 3Ohkawa Clinic, 4Ando Clinic, 5Total Support Clinic, 6Funabiki Clinic, 7Kume Clinic, Aichi, Japan
Background: In this study, we evaluated changes in functioning and caregiver burden in Alzheimer’s disease (AD) patients after a dosage increase that was made based on pharmacists’ evaluation of AD patients’ behavior in daily life.
Methods: Pharmacists used a checklist, a questionnaire, and the Repetitive Saliva Swallowing Test (RSST) to gather data on the daily life of AD patients taking donepezil 5 mg/day and their caregivers. In 27 cases, pharmacists suggested a dosage change to 10 mg/day to AD patients’ physicians. Pharmacists then evaluated these patients for 16 weeks after the increase to determine changes in functional assessment staging, caregiver burden, and swallowing function.
Results: During the 16-week study, 20 of the 27 patients showed at least one-stage improvement in relation to the five assessed aspects of daily life (time/place, speech, bathing, dressing, and toileting). The mean score for caregiver burden due to personal strain was significantly lower after the dosage increase than before (5.15±3.76 at baseline; from 3.89±3.42 at week 4 to 3.59±3.90 at week 16; P<0.05), as was the mean score due to role strain (2.19±2.80 at baseline; 1.56±2.64 at week 8; P<0.05). After the dosage increase, the impaired swallowing function that accompanies AD was improved in the patients with swallowing problems, as indicated by a higher mean RSST score (1.22±0.67 at baseline; from 2.78±1.72 at week 4 to 2.78±1.79 at week 16; P<0.05).
Conclusion: The dosage increase not only decreased caregiver burden, but also appeared to improve impaired swallowing function. Medication therapy management by pharmacists of AD patients, including the use of a checklist, contributed to the correct use of donepezil and improved quality of life for caregivers.
Keywords: Alzheimer’s disease, caregiver burden, behavior in daily life, swallowing function, checklist, pharmacists
Alzheimer’s disease (AD) is a progressive neurodegenerative disease in which serious cognitive dysfunction develops, and no curative treatment for AD has been established. At present, medications that delay the progression of symptoms are used in clinical settings. While the mortality rates for many leading causes of death have declined over the past decade, deaths from dementia have steadily increased.1 Dementia patients, their families, and health care providers must understand and be prepared to confront the end stage of this disease, which is estimated to affect more than 5 million Americans currently and is expected to affect more than 13 million by 2050.2 Similarly, the number of dementia patients is expected to grow in countries worldwide, including Japan, as the elderly population increases.
The increasing number of dementia patients accompanying the growing aging population is a serious social issue, especially for caregivers who support AD patients. As the disease progresses, AD patients often develop behavioral and psychosocial symptoms, such as wandering, agitation, sexually inappropriate behavior, depression, anxiety, and delusions. Loitering, delusions, and aggressive behavior, in particular, place a large burden on caregivers, both physically and psychologically. It can also be difficult for family members to immediately accept that a family member has become demented. As such, the burden on caregivers is due not only to frequent changes in the AD patient’s medical condition, but also to physical and psychological stress due to financial anxiety.
At present, pharmacological treatment for AD includes the acetylcholinesterase inhibitors donepezil hydrochloride (donepezil), galantamine hydrobromide, rivastigmine tartrate, and the N-methyl-D-aspartate receptor agonist memantine hydrochloride. Long-term administration of donepezil was reported to delay the progression of cognitive dysfunction over a period of 54 weeks.3 In addition to improving cognitive dysfunction, many studies have reported a positive relationship between donepezil and caregiver burden; for example, it can improve reduced movement in daily life,4 decrease the time needed for caregivers to watch AD patients,5 and improve scores on the Japanese version of the Zarit Caregiver Burden Interview (J-ZBI_8).6–8
However, since AD is a progressive neurodegenerative disease, the effect of donepezil gradually lessens over time. The dosage of donepezil must therefore be increased, at an appropriate time, from 5 mg/day to 10 mg/day as the severity of dementia progresses.9 In addition, since the prognosis of advanced dementia is unfavorable, as indicated by a 6-month survival rate of 25% and average life expectancy of 1.3 years from onset,10 it is desirable to increase the dosage as early as possible when AD progresses to advanced dementia. Increasing the dosage of donepezil is expected to improve not only decreased cognitive function but also improve the impaired swallowing function caused by refusal of some patients to eat due to dysphagia,11,12 and at the same time help to reduce caregiver burden.
In this study, with the overall aims of improving quality of life for AD patients and reducing caregiver burden by pharmacists recommending timely dosage increases in donepezil, pharmacists interviewed AD patients and their caregivers during medication therapy management and used a checklist for AD patients’ behavior in daily life to collect information on how patients were coping on a day-to-day basis. If the pharmacist judged it to be an appropriate time for a dosage increase, he or she proposed an increase to 10 mg/day to the AD patient’s physician. This increase may result in improved quality of life for both AD patients and their caregivers. Therefore, once the dosage was increased, the pharmacist examined the effectiveness of this increase on caregiver burden and on the changes in dementia severity and swallowing function.
Materials and methods
Among the patients diagnosed with AD between September 2012 and January 2014 at Ohkawa Clinic (Niwa, Japan), Kume Clinic (Nagoya, Japan), Funabiki Clinic (Inuyama, Japan), Total Support Clinic (Nagoya, Japan), and Andoh Clinic (Inuyama, Japan), we selected those who had taken donepezil 5 mg/day for more than 4 weeks and who agreed along with their caregivers to participate in this study. Pharmacists recommended a dosage increase of donepezil to 10 mg/day to AD patients’ physicians. Pharmacists then evaluated the AD patients for 16 weeks after the dosage increase to determine changes in functional assessment staging, caregiver burden, and swallowing function compared with baseline.
Pharmacists interviewed AD patients and caregivers and collected information on the patients’ behavior in daily life by means of a checklist (Table 1) based on functional assessment staging.13 AD stage was evaluated for the following five aspects of daily life: Q1) time and place, Q2) speech, Q3) bathing, Q4) dressing, and Q5) toileting. We evaluated items Q1 to Q4 in three stages (stages 4–6: from moderate to severe) and item 5 in two stages (stages 4 and 6). Improvement was defined as a one-stage improvement in AD stage compared with week 0, where week 0 was set as the time when donepezil (Aricept®) was first increased from 5 mg/day (baseline) to 10 mg/day. When AD patients were assessed to be at AD stage 5 or 6, the pharmacists suggested to the AD patients’ physicians that the dosage of donepezil be increased to 10 mg/day.
Table 1 Checklist of patient behavior in daily life
Caregiver burden was evaluated using the J-ZBI_8,6,7 which consists of eight items scored on a 5-point scale (0–4 points) that ask about personal strain (five items) and role strain (three items). The personal strain items are used to evaluate negative emotions regarding situations that require care, while role strain items are used to evaluate the severity of obstacles in the caregivers’ social life due to the care they provide for their family members with AD. The evaluation method entailed dividing the total score by the highest score to calculate a rate, which was set as 100% when caregiver burden was at maximum. The maximum caregiver burden score for personal strain was 20 points (five items × four points) and that for role strain was 12 points (three items × four points). Each score was evaluated as a rate in relation to the mean score divided by the maximum score (Table 2).
Changes in the AD patients’ swallowing function were assessed using the Repetitive Saliva Swallowing Test (RSST) by comparing function determined at week 0 with that determined at week 4, 8, 12, and 16. Swallowing three or more times in 30 seconds was regarded as normal, while swallowing twice or less in 30 seconds was considered impaired.14,15
Improvement in patients’ dementia severity was analyzed using the Fisher’s exact test. Changes in caregiver burden and swallowing function were analyzed using the Wilcoxon signed rank test in KaleidaGraph version 4.1.1 (Hulinks Inc., Tokyo, Japan). Statistical significance was determined at a probability of less than 5%.
This study was conducted after obtaining approval from the clinical study ethics committee at the School of Pharmacy, Aichi Gakuin University.
Patient and caregiver background
During the study, of the 35 patients who had their donepezil dosage increased to 10 mg/day, 27 (six men and 21 women, mean age 86.5±5.9 years) were included in the analysis. The remaining eight patients were excluded because they could not be followed continuously for 16 weeks; there were two deaths, two cases of decreased dosage due to side effects, and one transfer to another hospital, two showed poor adherence, and one was diagnosed with Parkinson’s disease as a underlying illness. Each of the 27 patients’ caregivers (20 family members, seven non-family members; two men and 25 women) were included in the analysis.
Improvements in dementia severity
Figure 1 shows the improvements in dementia severity seen in relation to time/place and speech compared with week 0. During the 16-week study, 20 of the 27 patients showed at least a one-stage improvement in severity. Improvement in severity in relation to time/place was seen in more than six patients during the 16-week study. Dementia severity was improved in relation to both aspects of time/place and speech in more than three patients during the 16-week study. However, the number of patients who showed improvement was not significantly different in relation to these two aspects during the 16-week study.
Figure 1 Improvement in dementia severity stage following the increase in donepezil to 10 mg/day.
Changes in caregiver burden
Table 3 shows changes in caregiver burden score compared with week 0. The mean J-ZBI_8 score for personal strain at week 0 was significantly decreased at all successive time points, from week 4 (P<0.05) to week 16 (P<0.01). The J-ZBI_8 score for role strain at week 0 was significantly decreased at week 8 (P<0.05).
Changes in swallowing function
Table 4 shows changes in swallowing function for 17 patients in whom the RSST could be performed on all five occasions. No significant changes were observed in AD patients with normal swallowing function. However, in AD patients with impaired swallowing function, the mean RSST score at week 0 was significantly improved at all successive time points (all P<0.05).
In this study, the increase in donepezil dosage from 5 mg/day to 10 mg/day not only improved the severity of dementia and decreased caregiver burden, but also appeared to improve the impaired swallowing function that can accompany AD. Following the dosage increase to 10 mg/day, AD stage was improved for two aspects of daily life assessed by the checklist (ie, time/place and speech), and in particular was significantly improved in relation to time and place. Kotani et al16 reported that donepezil acts in the rat brain at an early stage and the number of new neurons is increased 4 weeks after starting donepezil. The improvement seen in the cognitive dysfunction of AD by increasing the dosage of donepezil in this study indicates that this pharmacological action can be enhanced in a dose-dependent manner.
Caregiver burden decreased from week 4 to 16 following the increase in dosage to 10 mg/day. Specifically, personal strain was significantly decreased at week 16 compared with that at week 0; role strain was also decreased at week 16, although not significantly. The decreased burden on caregivers after increasing donepezil to 10 mg/day was likely the result of reducing the personal strain of caregivers, which in turn was probably the result of the decreased severity of dementia in the AD patients. Therefore, this improvement in caregiver burden was largely influenced by the amelioration of dementia severity in relation to time/place and speech, which are both factors that can lead to increased psychological strain in caregivers.
The improvements seen in AD stage for bathing, dressing, and toileting would also contribute to decreasing the burden of time that caregivers spent caring for AD patients. In this study, the scores were improved in 20 patients by at least one stage in the 16 weeks after the dosage increase. The checklist of AD patients’ behavior in daily life, based on functional assessment staging, was selected for use in this study because it is a simple tool encompassing the basic items that can indicate how AD patients are coping with daily life, and because it was expected to be an efficient measure for pharmacists and caregivers to complete. As a result of carrying out, we have confirmed the checklist useful for a better communication between pharmacists and AD patients’ physicians.
Since a relationship between dementia and dysphagia has been reported,11 the RSST was used in this study to determine if changes in swallowing function occurred after increasing the donepezil dosage. Swallowing problems are generally considered to be caused by esophageal retention17 and suppression of the cough reflex due to decreases in smooth and skeletal muscle function caused by anticholinergic medication.18 Since the acetylcholine concentration in AD patients is decreased, creating a condition similar to that where anticholinergic medications are needed, the increase in donepezil dosage would increase the acetylcholine concentration, thus improving esophageal smooth muscle function and thereby contributing to the improvement in swallowing problems. Our results show that the dosage increase significantly improved swallowing function at week 4, 8, 12, and 16 in AD patients with swallowing problems (RSST score ≤2) at baseline. These findings suggest that swallowing problems in AD patients will be improved after increasing the dosage of donepezil.
A limitation of this study was that the participating AD patients and caregivers did not receive any specialized counseling or training. In Japan, AD patients are typically cared for in their homes; therefore, in these situations, caregivers are usually family members and not professional caregivers. Family members of AD patients, including the patient’s spouse, children, and/or children-in-law, have varying levels and types of education. Greater variation in those parameters would be remained even if caregivers received any specialized counseling or training.
Dementia is a progressive disease, so it is difficult to stop its progression simply by increasing the donepezil dosage, despite its ability to temporarily improve symptoms. Similarly, caregiver burden may be temporarily reduced by increasing the dosage, but the burden will increase again as the AD patient’s symptoms progress. Therefore, it is necessary to provide continuous long-term support for AD patients and their caregivers. Part of the role of pharmacists is to provide support on medication adherence to AD patients and their caregivers as part of management of medication.19 Multidisciplinary teams composed of professionals from different disciplines, such as local public health, medicine, and social welfare, are also needed to provide such support. Based on the results of this study, a checklist of AD patients’ behavior in daily life is a convenient tool for pharmacists and caregivers to determine when the dosage of donepezil should be increased. A measure of caregiver burden is also valuable for ensuring safe use of medication and to monitor quality of life in both AD patients and their families.
The authors report no conflicts of interest in this work.
Hoyert DL, Kung HC, Smith BL. Deaths: preliminary data for 2003. Natl Vital Stat Rep. 2005;53:1–48.
Hebert LE, Scherr PA, Bienias JL. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60: 1119–1122.
Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001;57:481–488.
Winblad B, Black SE, Homma A, et al. Donepezil treatment in severe Alzheimer’s disease: a pooled analysis of three clinical trials. Curr Med Res Opin. 2009;25:2577–2587.
Wimo A, Winblad B, Shah SN, et al. Impact of donepezil treatment for Alzheimer’s disease on caregiver time. Curr Med Res Opin. 2004;20: 1221–1225.
Arai Y, Tamiya N, Yano E. [The short version of the Japanese version of the Zarit Caregiver Burden Interview (J-ZBI_8): its reliability and validity]. Nihon Ronen Igakkai Zasshi. 2003;40:497–503. Japanese.
Arai Y, Kudo K, Hosokawa T, et al. Reliability and validity of the Japanese version of the Zarit Caregiver Burden interview. Psychitry Clin Neurosci. 1997;51:281–287.
Hashimoto M, Yatabe Y, Kaneda K, et al. Impact of donepezil hydrochloride on the care burden of family caregivers of patients with Alzheimer’s disease. Psychogeriatrics. 2009;9:196–203.
Robert H, Rupert M, James L, et al. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med. 2012;366: 893–903.
Susan LM, Joan MT, Dan KK, et al. The clinical course of advanced dementia. N Engl J Med. 2009;361:1529–1538.
Kuzuya M, Enoki H, Izawa S, et al. Prevalence of oral intake difficulty and associated factors in disabled elderly. The Journal of Japanese Society for Parenteral and Enteral Nutrition. 2011;26:1265–1270.
Wasson K, Tate H, Hayes C. Food refusal and dysphagia in older people with dementia: ethical and practical issues. Int J Palliat Nurs. 2001; 7:465–71.
Reisberg B. Functional assessment staging (FAST). Psychopharmacol Bull. 1988;24:653–659.
Oguchi K, Saitoh E, Mizuno M, et al. The Repetitive Saliva Swallowing Test (RSST) as a screening test of functional dysphagia. (1) Normal values of RSST. Jpn J Rehabil Med. 2000;37:375–382.
Oguchi K, Saitoh E, Baba M, et al. The Repetitive Saliva Swallowing Test (RSST) as a screening test of functional dysphagia (2) Validity of RSST. Jpn J Rehabil Med. 2000;37:383–388.
Kotani S, Yamauchi T, Teramoto T, et al. Pharmacological evidence of cholinergic involvement in adult hippocampal neurogenesis in rats. Neuroscience. 2006;142:505–514.
Tsubouchi T, Tsujimoto S, Sugimoto S, et al. Swallowing disorder and inhibition of cough reflex induced by atropine sulfate in conscious dogs. J Pharmacol Sci. 2008;106:452–459.
Stoschus B, Allescher D. Drug-induced dysphagia. Dysphagia. 1993;8: 154–159.
Watanabe N, Yamamura K, Suzuki Y, et al. Pharmacist-based donepezil outpatient consultation service to improve medication persistence. Patient Prefer Adherence. 2012;6:605–611.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]